Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06027268 · ClinicalTrials.gov registry record · Phase 2

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

A Phase 2 study of Metastatic Triple-Negative Breast Cancer, sponsored by Wake Forest University Health Sciences.

Active
Registry status
Phase 2
Development phase
36
Enrollment target
1
Study location

NCT06027268 is a Phase 2 study of Metastatic Triple-Negative Breast Cancer that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 36 participants, below the 85-participant average among 5 other Metastatic Triple-Negative Breast Cancer trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06027268, a Phase 2 study of Metastatic Triple-Negative Breast Cancer, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The goal of this phase II study is to test the combination of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer. The main questions it aims to answer are: * to evaluate the anti-cancer efficacy (assess how well it works) * to evaluate the safety and tolerability (how well the body can handle the treatment) of this combination of anti-cancer therapy

Conditions Studied

Metastatic Triple-Negative Breast Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Gemcitabine
  • DRUG Trilaciclib

Study Locations (1)

North Carolina

  • Levine Cancer Institute - Charlotte

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2024-01-10
Est. Completion 2027-03
Phase Phase 2

Sponsor

Wake Forest University Health Sciences

1,140 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06027268

The ClinicalTrials.gov registry entry for NCT06027268 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 85-participant average among 5 other Metastatic Triple-Negative Breast Cancer trials with a reported enrollment target (58% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Triple-Negative Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT06027268 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06027268 about?

NCT06027268 is a clinical study titled "Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer". The goal of this phase II study is to test the combination of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer. The main questions it aims to answer are: * to evaluate the anti-cancer efficacy (assess how well it ...

What is the current status of trial NCT06027268?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2024-01-10. Estimated completion is 2027-03.

What conditions does trial NCT06027268 study?

This clinical trial studies the following conditions: Metastatic Triple-Negative Breast Cancer.

What interventions are being tested in trial NCT06027268?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Gemcitabine (DRUG), Trilaciclib (DRUG).

Who is sponsoring clinical trial NCT06027268?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06027268 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Triple-Negative Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Triple-Negative Breast Cancer

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.